ï»¿<!DOCTYPE html ><html><body><div>H-0187.1</div><hr style="margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;" /><div style="font-weight:bold;text-align:center;">HOUSE BILL 1062</div><hr style="margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;" /><table style="width:622px;margin-top:0.1in;"><tr><td><div style="font-weight:bold;">State of Washington</div></td><td><div style="font-weight:bold;">69th Legislature</div></td><td><div style="font-weight:bold;">2025 Regular Session</div></td></tr></table><div style="margin-top:0.1in;"><span style="font-weight:bold;margin-right:0.25in;">By</span><!-- field: Sponsors -->Representatives Stonier, Corry, Parshley, Thai, Macri, Ryu, Leavitt, Berry, Reed, Alvarado, Callan, Tharinger, Fosse, Simmons, Davis, Ormsby, Reeves, Bernbaum, Donaghy, and Hill<!-- field: --></div><div style="margin-top:0.1in;"><span style="margin-right:0.25in;">Prefiled 12/13/24.</span><span style="margin-right:0.25in;">Read first time 01/13/25.</span><span style="margin-right:0.25in;">Referred to Committee on Health Care &amp; Wellness.</span></div><div style="text-indent:0.5in;margin-top:0.5in;"><!-- field: CaptionsTitles -->AN ACT Relating to coverage for biomarker testing; adding a new section to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43'>48.43</a> RCW; adding a new section to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=41.05'>41.05</a> RCW; and adding a new section to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=74.09'>74.09</a> RCW.<!-- field: --></div><div style="margin-top:0.25in;margin-bottom:0.25in;">BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:</div><div style="margin-top:0.25in;text-indent:0.5in;"><!-- field: BeginningSection --><span style="text-decoration:underline;">NEW SECTION.</span><span>Â Â </span><span style="font-weight:bold;padding-right:0.1in;">Sec. 1.  </span>A new section is added to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43'>48.43</a> RCW to read as follows:<!-- field: --></div><div style="text-indent:0.5in;"><!-- field: Text -->(1) For health plans issued or renewed on or after January 1, 2026, a health carrier shall include coverage for biomarker testing pursuant to the criteria established under subsection (2) of this section.</div><div style="text-indent:0.5in;">(2) Biomarker testing must be covered for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence including, but not limited to:</div><div style="text-indent:0.5in;">(a) Labeled indications for tests approved or cleared by the United States food and drug administration or indicated tests for a drug approved by the United States food and drug administration;</div><div style="text-indent:0.5in;">(b) Centers for medicare and medicaid services national coverage determinations or medicare administrative contractor local coverage determinations;</div><div style="text-indent:0.5in;">(c) Nationally recognized clinical practice guidelines; or</div><div style="text-indent:0.5in;">(d) Consensus statements.</div><div style="text-indent:0.5in;">(3) Health carriers shall ensure coverage as required in subsection (2) of this section is provided in a manner that limits disruptions in care including the need for multiple biopsies or biospecimen samples.</div><div style="text-indent:0.5in;">(4) For the purposes of this section:</div><div style="text-indent:0.5in;">(a) "Biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention. Biomarkers include but are not limited to gene mutations or protein expression.</div><div style="text-indent:0.5in;">(b) "Biomarker testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests, multiplex panel tests, and whole genome sequencing.</div><div style="text-indent:0.5in;">(c) "Consensus statements" means statements that are:</div><div style="text-indent:0.5in;">(i) Developed by an independent, multidisciplinary panel of experts utilizing a transparent methodology and reporting structure and with a conflict of interest policy;</div><div style="text-indent:0.5in;">(ii) Aimed at specific clinical circumstances; and</div><div style="text-indent:0.5in;">(iii) Based on the best available evidence for the purpose of optimizing the outcomes of clinical care.</div><div style="text-indent:0.5in;">(d) "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that:</div><div style="text-indent:0.5in;">(i) Are developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy;</div><div style="text-indent:0.5in;">(ii) Establish standards of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options; and</div><div style="text-indent:0.5in;">(iii) Include recommendations intended to optimize patient care.</div><!-- field: --><div style="margin-top:0.25in;text-indent:0.5in;"><!-- field: BeginningSection --><span style="text-decoration:underline;">NEW SECTION.</span><span>Â Â </span><span style="font-weight:bold;padding-right:0.1in;">Sec. 2.  </span>A new section is added to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=41.05'>41.05</a> RCW to read as follows:<!-- field: --></div><div style="text-indent:0.5in;"><!-- field: Text -->(1) A health plan offered to public employees and their covered dependents under this chapter issued or renewed on or after January 1, 2026, shall include coverage for biomarker testing pursuant to the criteria established under subsection (2) of this section.</div><div style="text-indent:0.5in;">(2) Biomarker testing must be covered for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence including, but not limited to:</div><div style="text-indent:0.5in;">(a) Labeled indications for tests approved or cleared by the United States food and drug administration or indicated tests for a drug approved by the United States food and drug administration;</div><div style="text-indent:0.5in;">(b) Centers for medicare and medicaid services national coverage determinations or medicare administrative contractor local coverage determinations;</div><div style="text-indent:0.5in;">(c) Nationally recognized clinical practice guidelines; or</div><div style="text-indent:0.5in;">(d) Consensus statements.</div><div style="text-indent:0.5in;">(3) A health plan offered to public employees and their covered dependents shall ensure coverage as required in subsection (2) of this section is provided in a manner that limits disruptions in care including the need for multiple biopsies or biospecimen samples.</div><div style="text-indent:0.5in;">(4) For purposes of this section, "biomarker," "biomarker testing," "consensus statements," and "nationally recognized clinical practice guidelines" all have the same meaning as defined in section 1 of this act.</div><!-- field: --><div style="margin-top:0.25in;text-indent:0.5in;"><!-- field: BeginningSection --><span style="text-decoration:underline;">NEW SECTION.</span><span>Â Â </span><span style="font-weight:bold;padding-right:0.1in;">Sec. 3.  </span>A new section is added to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=74.09'>74.09</a> RCW to read as follows:<!-- field: --></div><div style="text-indent:0.5in;"><!-- field: Text -->(1) Beginning January 1, 2026, the authority shall provide coverage under this chapterÂ for biomarker testing pursuant to the criteria established under subsection (2) of this section.</div><div style="text-indent:0.5in;">(2) Biomarker testing must be covered for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence including, but not limited to:</div><div style="text-indent:0.5in;">(a) Labeled indications for tests approved or cleared by the United States food and drug administration or indicated tests for a drug approved by the United States food and drug administration;</div><div style="text-indent:0.5in;">(b) Centers for medicare and medicaid services national coverage determinations or medicare administrative contractor local coverage determinations;</div><div style="text-indent:0.5in;">(c) Nationally recognized clinical practice guidelines; or</div><div style="text-indent:0.5in;">(d) Consensus statements.</div><div style="text-indent:0.5in;">(3) The authority shall ensure coverage as required in subsection (2) of this section is provided in a manner that limits disruptions in care including the need for multiple biopsies or biospecimen samples.</div><div style="text-indent:0.5in;">(4) In administering this program, the authority shall seek any available federal financial participation under the medical assistance program, as codified at Title XIX of the federal social security act, or any other federal funding sources that are now available or may become available.</div><div style="text-indent:0.5in;">(5) For purposes of this section, "biomarker," "biomarker testing," "consensus statements," and "nationally recognized clinical practice guidelines" all have the same meaning as defined in section 1 of this act.</div><!-- field: --><div style="margin-top:0.1in;font-weight:bold;text-align:center;">--- END ---</div></body></html>